Author:
Penson R T,Seiden M V,Matulonis U A,Appleman L J,Fuller A F,Goodman A,Campos S M,Clark J W,Roche M,Eder J P
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN (1996) Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Clin Cancer Res 2: 1489–1497
2. Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, Kurata T, Kasai T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Kakinuma R, Nishiwaki Y, Saijo N (1997) Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer 76: 1494–1499
3. Burris III HA, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rinaldi DA, Fields S, Smith L, Von Hoff DD (1994) Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 5: 394–402
4. Cannistra SA (1999) Back to the future: multiagent chemotherapy in ovarian cancer revisited. J Clin Oncol 17: 741–743
5. Cannistra SA (2002) Is there a ‘best’ choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20: 1158–1160
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献